By Fineline Cube 
Samsung Bioepis Co., Ltd. today announced a strategic, worldwide partnership with Phrontline Biopharma to jointly develop, manufacture, and commercialise two antibody‑drug conjugate (ADC) assets, including the bispecific, dual‑payload ADC TJ108 and a second, unnamed ADC. Under the agreement, Samsung Bioepis will also receive an exclusive licence to a topoisomerase‑1 (TOP1) payload for use across its ADC pipeline.
Key Elements of the Collaboration
- Joint Development & Manufacturing – Samsung Bioepis and Phrontline will share expertise in pre‑clinical, clinical and manufacturing processes for both ADCs.
- Exclusive Payload License – Samsung Bioepis gains sole rights to one TOP1 payload, enhancing its ADC design flexibility.
- Financial Terms – Phrontline will receive an upfront payment, plus milestone payments tied to development milestones and regulatory approvals.
About TJ108
| Feature | Detail |
|---|---|
| Target | Dual‑specificity for EGFR & HER3, over‑expressed in many solid tumours |
| Payloads | 1) Topoisomerase‑1 inhibitor (TOP1) 2) Tubulin inhibitor |
| Mechanism | Combines immune‑checkpoint blockade with dual‑mode cytotoxicity for enhanced tumour penetration and bystander killing |
| Clinical Outlook | Early pre‑clinical data show superior efficacy in EGFR‑/HER3‑driven models; clinical studies slated for Q4 2026 |
Strategic Fit for Samsung Bioepis
- Beyond Biosimilars – The partnership marks a deliberate shift toward innovative therapies, diversifying Samsung Bioepis’ portfolio.
- Broad Therapeutic Coverage – Current pipeline spans immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology.
- Unmet Needs – ADCs target aggressive cancers with limited treatment options, aligning with the company’s mission to broaden patient access.
Forward‑Looking Statements
Statements in this release that are not historical facts are forward‑looking and involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech